Trial Profile

Phase II study of RG-101 and GSK2878175 in patients chronically infected with HCV.

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to a Novartis media release, Regulus Therapeutics has been acquired and merged into Novartis.
27 Jan 2017 According to a Regulus Therapeutics media release, company received written communication from the U.S. Food and Drug Administration (FDA) to continue clinical hold on RG-101 clinical development program. FDA has requested the final safety and efficacy data from on-going RG-101 studies before reconsidering the clinical hold. Company is planning an additional requests with US FDA to seek the release of the clinical hold.
27 Jun 2016 According to a Regulus Therapeutics media release, the company plans to work with US FDA to seek the release of the clinical hold.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com